Emerging Needle-Free Epinephrine Treatments Show Promise in Clinical Trials
New intranasal and sublingual epinephrine delivery methods are demonstrating faster absorption and effectiveness in mid-stage clinical trials compared to traditional autoinjectors.
🔬ResearchPhoto: medpagetoday.com
Key points
- Intranasal epinephrine powder showed faster absorption than traditional autoinjectors in simulated congestion trials.
- A novel sublingual epinephrine film demonstrated rapid symptom resolution and consistent pharmacokinetic profiles.
- Both treatments were generally well-tolerated with no serious cardiovascular adverse events reported in these early-stage studies.
Recent clinical research presented at the American College of Allergy, Asthma & Immunology annual meeting suggests that needle-free epinephrine options may soon provide alternatives to traditional autoinjectors for managing severe allergic reactions. Researchers evaluated two novel delivery systems: an intranasal powder formulation known as NS002 and a dissolvable sublingual film called dibutepinephrine.
In a phase II study involving 50 adults with allergic rhinitis, the NS002 nasal powder achieved higher plasma epinephrine levels more rapidly than standard autoinjectors, even when nasal congestion was induced to mimic anaphylactic symptoms. The study found that NS002 reached critical clinical thresholds two to four times faster than the EpiPen. Participants reported the treatment was well-tolerated, with only minor, transient local side effects such as nasal discomfort and congestion.
A separate phase II study of 110 healthy adults tested the sublingual film, dibutepinephrine. Data indicated that this dissolvable film reached peak blood concentration levels faster than conventional intramuscular injections or autoinjectors. Furthermore, the film demonstrated consistent performance across different testing scenarios, including in subjects experiencing localized oral allergic reactions.
What to know: These findings are based on mid-stage, phase II trials. While the results are promising, these treatments are still undergoing evaluation, and larger phase III studies are required to confirm efficacy and safety. Patients should continue to use prescribed autoinjectors and consult with their healthcare provider regarding any changes to their allergy management plan.
Source medpagetoday.com — medpagetoday.com/meetingcoverage/acaai/123917 ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…